Cancer research is a complex, multi-faceted journey that does not begin with clinical trials, requiring a critical link from discovery science in the lab to treatments delivered in the clinic—a process often called 'bench to bedside.

Without this translational component, new discoveries slow down, and patient access to innovative treatments is hindered. This episode explores how to foster this essential cycle, addressing current challenges like funding for translational research, the need for greater integration and collaboration across the island of Ireland, and the vital role of industry partnerships. The discussion highlights key findings from the All-Ireland Cancer Research Institute (ACRI) Landscape Report and the growing impact of patient-led studies like ProAct.

Host Dr. Ciara Kelly is joined by two of Ireland’s leading cancer experts: Professor Liam Gallagher, Professor of Cancer Biology at UCD and Co-Lead of the All-Ireland Cancer Research Institute, and Angela Clayton-Lea, the CEO of Cancer Trials Ireland.

THINGS WE SPOKE ABOUT

Professor Gallagher's path to cancer biology.

The cycle of bench-to-bedside research.

HRB translational research funding challenges.

Why all-island collaboration is extremely important.

Patient-led research and the ProAct project.

MORE INFORMATION

https://www.cancertrials.ie

Hosted on Acast. See acast.com/privacy for more information.